131 results about "Campylobacter" patented technology

The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.

Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular of poultry are provided herein. The methods include administering an endospore-forming bacteria to an animal. The bacteria are selected for the ability to reduce the growth and presence of bacterial pathogens, such as Salmonella, Clostridium, and Campylobacter, in the gastrointestinal tract of the animal. The bacteria are also selected for the ability to improve at least one production parameter in the animal.

The present invention provide a composition of non-toxic low-cost ingredients that effectively kill pathologic bacteria and methods for use of the composition. The present invention comprises novel compositions and methods for controlling enteric pathogens and spoilage organisms such as Salmonella, Escherichia, Campylobacter, Listeria, Pseudomonas and Enterobacteracae on the surface of meat products and food preparation surfaces.

The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.

Xylanase or a cellulase for the manufacture of an agent for the treatment and / or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens. It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective in controlling Campylobacter and Salmonella in chickens. The use provided by the present invention affords an alternative to antibiotics when controlling bacterial infection in animals. This leads to considerable health, environmental and economic benefits.

The present invention provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and / or reduce intestinal colonization by Campylobacter.

The field of this invention is the development of therapeutic agents having immunogenic efficacy against Campylobacter. The present invention is directed to a method of producing monoclonal antibodies that are highly specific for epitopes of Campylobacter jejuni outer membrane proteins; to specific monoclonal antibodies made by using the epitopes; and to uses thereof. The invention is drawn further to immunogens comprising certain outer membrane proteins or portions thereof from C. jejuni.

The disclosed method simultaneously and specifically detects at least two types of food-poisoning bacteria from among Escherichia coli, Listeria, Campylobacter, Vibrio parahaemolyticus, Staphylococcus aureus, Salmonella, and Bacillus cereus. The food-poisoning bacteria detection carrier immobilizes one or at least two probes selected from each of at least two groups from among: an E. coli-detecting first probe group comprising the probes of sequence numbers 1-6 and probes (hereinafter written as "and the like") that are complementary thereto; a Listeria-detecting second probe group comprising the probes of sequence numbers 7-13, and the like; a Campylobacter-detecting third probe group comprising the probes of sequence numbers 14-19, and the like; a Vibrio parahaemolyticus-detecting fourth probe group comprising the probes of sequence numbers 20-24, and the like; a Staphylococcus aureus-detecting fifth probe group comprising the probes of sequence numbers 25-29, and the like; a Salmonella-detecting sixth probe group comprising the probes of sequence numbers 30-40, and the like; and a Bacillus cereus-detecting seventh probe group comprising the probes of sequence numbers 41-49.

The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof as well as methods for treating and / or preventing Campylobacter and optionally Salmonella infections and methods for producing these Salmonella strains.